EX-3.1
from 8-K
31 pages
2 This Presentation Includes Statements That Are “Forward-Looking Statements.” Forward-Looking Statements Include, Without Limitation, Our Ability (I) to Timely Commence and Complete Our Clinical Programs,(ii) to Successfully Genetically Modify the Fibroblast Cell to Treat Patients Who Have Collagen Deficient Diseases, (III) to Successfully Leverage Our Relationships With Ucla and Mit to Develop New Applications, and (IV) to Adopt Technologies That Will Dramatically Reduce Manufacturing Time, Complexity, and Labor Costs for Our Cell Therapies. While Management Has Based Any Forward-Looking Statements Contained in the Presentation on Its Current Expectations, the Information on Which Such Expectations Were Based May Change. These Forward-Looking Statements Rely on a Number of Assumptions Concerning Future Events and Are Subject to a Number of Risks, Uncertainties, and Other Factors, Many of Which Are Outside of Fibrocell Science’s Control, That Could Cause Actual Results to Materially Differ From Such Statements. Such Risks, Uncertainties, and Other Factors Include, but Are Not Necessarily Limited To, Those Set Forth Under the Caption “Item 1a. Risk Factors” in Fibrocell Science’s Most Recent Form 10-K Filing, as Updated in “Item 1a. Risk Factors” in Fibrocell Science’s Most Recent Form 10-Q Filing. in Addition, Fibrocell Science Operates in a Highly Competitive and Rapidly Changing Environment, and New Risks May Arise. Accordingly, You Should Not Place Any Reliance on Forward-Looking Statements as a Prediction of Actual Results. Fibrocell Science Disclaims Any Intention To, and Undertakes No Obligation To, Update or Revise Any Forward-Looking Statement. You Are Also Urged to Carefully Review and Consider the Various Disclosures in Fibrocell Science’s Most Recent Annual Report on Form 10-K, Our Most Recent Form 10-Q as Well as Other Public Filings With the SEC Since the Filing of Fibrocell Science’s Most Recent Annual Report. Forward Looking Statement
12/34/56
